Cue Biopharma Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
/ 
Frequently asked questions
To buy Cue Biopharma Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Cue Biopharma Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Cue Biopharma Inc. is CUE:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Cue Biopharma Inc. has its primary listing on NASDAQ (Small cap). You can trade Cue Biopharma Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Cue Biopharma Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Cue Biopharma Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Cue Biopharma Inc..